Stefano Fais

List of Publications by Year
in descending order

#	Article	IF	Citations
1	What we know on the potential use of exosomes for nanodelivery. Seminars in Cancer Biology, 2022, 86, 13-25.	9.6	16
2	Extracellular vesicles in cancer pros and cons: The importance of the evidence-based medicine. Seminars in Cancer Biology, 2022, 86, 4-12.	9.6	12
3	The Potentiality of Plant-Derived Nanovesicles in Human Healthâ€"A Comparison with Human Exosomes and Artificial Nanoparticles. International Journal of Molecular Sciences, 2022, 23, 4919.	4.1	24
4	Proton pump inhibitors and other pH-buffering agents. , 2021, , 47-62.		0
5	Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. International Journal of Molecular Sciences, 2021, 22, 4367.	4.1	62
6	New hypotheses for cancer generation and progression. Medical Hypotheses, 2021, 152, 110614.	1.5	4
7	Nanovesicles from Organic Agriculture-Derived Fruits and Vegetables: Characterization and Functional Antioxidant Content. International Journal of Molecular Sciences, 2021, 22, 8170.	4.1	25
8	Nanovesicles released by OKT3 hybridoma express fully active antibodies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 175-182.	5.2	12
9	Plasmatic Exosome Number and Size Distinguish Prostate Cancer Patients From Healthy Individuals: A Prospective Clinical Study. Frontiers in Oncology, 2021, 11, 727317.	2.8	28
10	Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opinion on Therapeutic Patents, 2020, 30, 15-25.	5.0	31
11	Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 280-288.	5.2	47
12	Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era. International Journal of Molecular Sciences, 2020, 21, 7475.	4.1	4
13	The Pentose Phosphate Pathway Dynamics in Cancer and Its Dependency on Intracellular pH. Metabolites, 2020, 10, 285.	2.9	68
14	Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids. Methods in Enzymology, 2020, 645, 155-180.	1.0	41
15	The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. Cancers, 2020, 12, 3226.	3.7	17
16	Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences, 2020, 21, 5432.	4.1	33
17	Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial. Cancers, 2020, 12, 3084.	3.7	4
18	Exosomes: A Source for New and Old Biomarkers in Cancer. Cancers, 2020, 12, 2566.	3.7	45

#	Article	IF	Citations
19	Anti-aging and anti-tumor effect of FPPÂ® supplementation. European Journal of Translational Myology, 2020, 30, 58-61.	1.7	3
20	Vacuolar-ATPase proton pump inhibition in cancer therapy: Veterinary and human experience. , 2020, , 509-522.		0
21	A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics. International Journal of Molecular Sciences, 2020, 21, 1110.	4.1	10
22	<i>In vivo</i> antiaging effects of alkaline water supplementation. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 657-664.	5.2	10
23	Lipidomic analysis of cancer cells cultivated at acidic pH reveals phospholipid fatty acids remodelling associated with transcriptional reprogramming. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 963-973.	5.2	16
24	The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer. Cancers, 2020, 12, 898.	3.7	35
25	Beneficial Effects of Fermented Papaya Preparation (FPPÂ®) Supplementation on Redox Balance and Aging in a Mouse Model. Antioxidants, 2020, 9, 144.	5.1	12
26	Why research in medicine needs a step back? Editorial. Annali Dell'Istituto Superiore Di Sanita, 2020, 56, 3-5.	0.4	1
27	Unexpected Discoveries Should Be Reconsidered in Scienceâ€”A Look to the Past?. International Journal of Molecular Sciences, 2019, 20, 3973.	4.1	7
28	Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. Cancers, 2019, 11, 1449.	3.7	73
29	Oral Administration of Fermented Papaya (FPPÂ®) Controls the Growth of a Murine Melanoma through the In Vivo Induction of a Natural Antioxidant Response. Cancers, 2019, 11, 118.	3.7	9
30	Targeting acidity in cancer and diabetes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 273-280.	7.4	70
31	Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer and Metastasis Reviews, 2019, 38, 93-101.	5.9	99
32	Causes, consequences, and therapy of tumors acidosis. Cancer and Metastasis Reviews, 2019, 38, 205-222.	5.9	200
33	A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients. Cancers, 2019, 11, 429.	3.7	68
34	The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management. Frontiers in Oncology, 2019, 9, 75.	2.8	64
35	Human primary macrophages scavenge AuNPs and eliminate it through exosomes. A natural shuttling for nanomaterials. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 137, 23-36.	4.3	48
36	Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 272-278.	5.2	59

#	Article	IF	Citations
37	On the Choice of the Extracellular Vesicles for Therapeutic Purposes. International Journal of Molecular Sciences, 2019, 20, 236.	4.1	81
38	Exosomal Hsp60: A Tumor Biomarker?. Heat Shock Proteins, 2019, , 107-116.	0.2	1
39	Cell-in-cell phenomena, cannibalism, and autophagy: is there a relationship?. Cell Death and Disease, 2018, 9, 95.	6.3	17
40	The key role of extracellular vesicles in the metastatic process. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 64-77.	7.4	119
41	Cell-in-cell phenomena in cancer. Nature Reviews Cancer, 2018, 18, 758-766.	28.4	132
42	A Role of Tumor-Released Exosomes in Paracrine Dissemination and Metastasis. International Journal of Molecular Sciences, 2018, 19, 3968.	4.1	53
43	Moving the systemic evolutionary approach to cancer forward: Therapeutic implications. Medical Hypotheses, 2018, 121, 80-87.	1.5	13
44	Microenvironmental pH and Exosome Levels Interplay in Human Cancer Cell Lines of Different Histotypes. Cancers, 2018, 10, 370.	3.7	141
45	Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy. Metabolites, 2018, 8, 2.	2.9	51
46	Exosomal Chaperones and miRNAs in Gliomagenesis: State-of-Art and Theranostics Perspectives. International Journal of Molecular Sciences, 2018, 19, 2626.	4.1	34
47	Out of Warburg effect: An effective cancer treatment targeting the tumor specific metabolism and dysregulated pH. Seminars in Cancer Biology, 2017, 43, 134-138.	9.6	108
48	Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?. Seminars in Cancer Biology, 2017, 43, 111-118.	9.6	48
49	European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD). European Journal of Pharmaceutical Sciences, 2017, 98, 1-3.	4.0	10
50	Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 648-657.	5.2	97
51	Systemic alkalinisation delays prostate cancer cell progression in TRAMP mice. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 363-368.	5.2	18
52	Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment. Expert Review of Molecular Diagnostics, 2017, 17, 815-822.	3.1	74
53	Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 908-916.	5.2	44
54	Increased PSA expression on prostate cancer exosomes in inÂvitro condition and in cancer patients. Cancer Letters, 2017, 403, 318-329.	7.2	196

#	Article	IF	Citations
55	Reprint of â€œEXOSOME LEVELS IN HUMAN BODY FLUIDS: A TUMOR MARKER BY THEMSELVES?â€• European Journal of Pharmaceutical Sciences, 2017, 98, 64-69.	4.0	7
56	Novel Instruments for the Implementation of Electrochemotherapy Protocols: From Bench Side to Veterinary Clinic. Journal of Cellular Physiology, 2017, 232, 490-495.	4.1	19
57	Exosome levels in human body fluids: A tumor marker by themselves?. European Journal of Pharmaceutical Sciences, 2017, 96, 93-98.	4.0	148
58	Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. Oncotarget, 2017, 8, 4147-4155.	1.8	12
59	Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget, 2016, 7, 50086-50098.	1.8	124
60	Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice. PLoS ONE, 2016, 11, e0159763.	2.5	31
61	Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Letters, 2016, 376, 278-283.	7.2	56
62	Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 119-125.	5.2	54
63	High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. Digestive and Liver Disease, 2016, 48, 1503-1505.	0.9	35
64	Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial. Clinical Colorectal Cancer, 2016, 15, 377-380.	2.3	23
65	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. ACS Nano, 2016, 10, 3886-3899.	14.6	397
66	A nonmainstream approach against cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 882-889.	5.2	24
67	Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 538-545.	5.2	47
68	The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells. Oncotarget, 2016, 7, 28849-28867.	1.8	56
69	Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 2015, 4, 27066.	12.2	3,973
70	Applying extracellular vesicles based therapeutics in clinical trials â€“ an ISEV position paper. Journal of Extracellular Vesicles, 2015, 4, 30087.	12.2	1,020
71	Evidence-based support for the use of proton pump inhibitors in cancer therapy. Journal of Translational Medicine, 2015, 13, 368.	4.4	50
72	Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. Cancer, 2015, 121, 3230-3239.	4.1	131

#	Article	IF	Citations
73	Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols. Current Cancer Drug Targets, 2015, 16, 43-52.	1.6	31
74	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. PLoS ONE, 2015, 10, e0126526.	2.5	10
75	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene, 2015, 34, 5163-5174.	5.9	69
76	Proton channels and exchangers in cancer. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2715-2726.	2.6	158
77	Exosomal clusterin, identified in the pericardial fluid, improves myocardial performance following MI through epicardial activation, enhanced arteriogenesis and reduced apoptosis. International Journal of Cardiology, 2015, 197, 333-347.	1.7	71
78	Detection of exosomal prions in blood by immunochemistry techniques. Journal of General Virology, 2015, 96, 1969-1974.	2.9	37
79	Proton pump inhibitors for the treatment of cancer in companion animals. Journal of Experimental and Clinical Cancer Research, 2015, 34, 93.	8.6	31
80	Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resistance Updates, 2015, 23, 69-78.	14.4	202
81	Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. Journal of Experimental and Clinical Cancer Research, 2015, 34, 85.	8.6	131
82	Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Letters, 2015, 356, 697-703.	7.2	81
83	Cancer Cell Cannibalism: A Primeval Option to Survive.. Current Molecular Medicine, 2015, 15, 836-841.	1.3	29
84	â€œI Have a Dreamâ€. Journal of Circulating Biomarkers, 2014, 3, 5.	1.3	0
85	Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer and Metastasis Reviews, 2014, 33, 1095-1108.	5.9	146
86	Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs. Frontiers in Oncology, 2014, 4, 267.	2.8	85
87	High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 2014, 12, 225.	4.4	77
88	Soma-to-Germline Transmission of RNA in Mice Xenografted with Human Tumour Cells: Possible Transport by Exosomes. PLoS ONE, 2014, 9, e101629.	2.5	125
89	Exosomal Heat Shock Proteins as New Players in Tumour Cell-to-Cell Communication. Journal of Circulating Biomarkers, 2014, 3, 4.	1.3	33
90	Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE, 2014, 9, e88193.	2.5	300

#	Article	IF	Citations
91	Exosomes released in vitro from Epsteinâ€"Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs. Cancer Letters, 2013, 337, 193-199.	7.2	78
92	Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs â€" an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. Journal of Translational Medicine, 2013, 11, 282.	4.4	135
93	Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patientsâ€™ bed. Journal of Translational Medicine, 2013, 11, 268.	4.4	115
94	Exosomes: the future of biomarkers in medicine. Biomarkers in Medicine, 2013, 7, 769-778.	1.4	342
95	Exosomes: the ideal nanovectors for biodelivery. Biological Chemistry, 2013, 394, 1-15.	2.5	79
96	NK cell-released exosomes. OncoImmunology, 2013, 2, e22337.	4.6	72
97	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. OncoImmunology, 2013, 2, e22058.	4.6	121
98	Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Research, 2012, 72, 2746-2756.	0.9	470
99	Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress. Journal of Biological Chemistry, 2012, 287, 30664-30676.	3.4	153
100	A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents. Current Pharmaceutical Design, 2012, 18, 1395-1406.	1.9	50
101	Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity. Current Pharmaceutical Design, 2012, 18, 1414-1420.	1.9	31
102	Immune Surveillance Properties of Human NK Cell-Derived Exosomes. Journal of Immunology, 2012, 189, 2833-2842.	0.8	358
103	TM9 and cannibalism: how to learn more about cancer by studying amoebae and invertebrates. Trends in Molecular Medicine, 2012, 18, 4-5.	6.7	34
104	Pâ€glycoprotein binds to ezrin at amino acid residues 149â€"242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma. International Journal of Cancer, 2012, 130, 2824-2834.	5.1	56
105	Abstract P6-11-01: Intermittent High Dose Proton Pump Inhibitor Improves Progression Free Survival as Compared to Standard Chemotherapy in the First Line Treatment of Patients with Metastatic Breast Cancer. , 2012, , .		0
106	Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. Journal of Translational Medicine, 2011, 9, 221.	4.4	78
107	pHâ€dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, 2010, 127, 207-219.	5.1	237
108	Moulding the shape of a metastatic cell. Leukemia Research, 2010, 34, 843-847.	0.8	7

#	Article	IF	Citations
109	Application of acoustic techniques in the evaluation of heterogeneous building materials. NDT and E International, 2010, 43, 62-69.	3.7	18
110	Proton pump inhibitorâ€induced tumour cell death by inhibition of a detoxification mechanism. Journal of Internal Medicine, 2010, 267, 515-525.	6.0	92
111	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death and Disease, 2010, 1, e87-e87.	6.3	155
112	Proton dynamics in cancer. Journal of Translational Medicine, 2010, 8, 57.	4.4	97
113	Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. Journal of Experimental and Clinical Cancer Research, 2010, 29, 44.	8.6	100
114	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. PLoS ONE, 2009, 4, e5219.	2.5	806
115	Pleiotropic function of ezrin in human metastatic melanomas. International Journal of Cancer, 2009, 124, 2804-2812.	5.1	41
116	The Janusâ€faced role of ezrin in â€œlinkingâ€•cells to either normal or metastatic phenotype. International Journal of Cancer, 2009, 125, 2239-2245.	5.1	52
117	The human homologue of <i>Dictyostelium discoideum</i> phg1A is expressed by human metastatic melanoma cells. EMBO Reports, 2009, 10, 1348-1354.	4.5	57
118	Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells. Journal of Biological Chemistry, 2009, 284, 34211-34222.	3.4	1,207
119	Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Letters, 2009, 280, 110-119.	7.2	82
120	Massive Secretion by T Cells Is Caused by HIV Nef in Infected Cells and by Nef Transfer to Bystander Cells. Cell Host and Microbe, 2009, 6, 218-230.	11.0	151
121	How to Overcome Cisplatin Resistance Through Proton Pump Inhibitors. , 2009, , 109-114.		1
122	Tumour-released exosomes and their implications in cancer immunity. Cell Death and Differentiation, 2008, 15, 80-88.	11.2	452
123	More insights into the immunosuppressive potential of tumor exosomes. Journal of Translational Medicine, 2008, 6, 63.	4.4	33
124	Proton Pump Inhibitors Induce Apoptosis of Human B-Cell Tumors through a Caspase-Independent Mechanism Involving Reactive Oxygen Species. Cancer Research, 2007, 67, 5408-5417.	0.9	280
125	Potential Role for IL-7 in Fas-Mediated T Cell Apoptosis During HIV Infection. Journal of Immunology, 2007, 178, 5340-5350.	0.8	40
126	Cannibalism: A way to feed on metastatic tumors. Cancer Letters, 2007, 258, 155-164.	7.2	132

#	Article	IF	Citations
127	Targeting Vacuolar H+-ATPases as a New Strategy against Cancer. Cancer Research, 2007, 67, 10627-10630.	0.9	247
128	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene, 2006, 25, 3357-3364.	5.9	157
129	Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells. Cancer Research, 2006, 66, 3629-3638.	0.9	242
130	Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-Î²â€"Mediated Suppressive Activity on T Lymphocytes. Cancer Research, 2006, 66, 9290-9298.	0.9	455
131	The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 941-947.	4.9	41
132	Proton pump inhibitors may reduce tumour resistance. Expert Opinion on Pharmacotherapy, 2005, 6, 1049-1054.	1.8	64
133	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. Expert Opinion on Biological Therapy, 2005, 5, 463-476.	3.1	63
134	Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncology, 2005, 1, 779-786.	2.4	232
135	Human Colorectal Cancer Cells Induce T-Cell Death Through Release of Proapoptotic Microvesicles: Role in Immune Escape. Gastroenterology, 2005, 128, 1796-1804.	1.3	453
136	Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. Journal of the National Cancer Institute, 2004, 96, 1702-1713.	6.3	395
137	Identification and Relevance of the CD95-binding Domain in the N-terminal Region of Ezrin. Journal of Biological Chemistry, 2004, 279, 9199-9207.	3.4	53
138	Effect Of Human Natural Killer and Î³Î´ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.9	90
139	CD95/phosphorylated ezrin association underlies HIV-1 GP120/IL-2-induced susceptibility to CD95(APO-1/Fas)-mediated apoptosis of human resting CD4+T lymphocytes. Cell Death and Differentiation, 2004, 11, 574-582.	11.2	32
140	Comparison of ultrasonic velocity and IR thermography for the characterisation of stones. Infrared Physics and Technology, 2004, 46, 63-68.	2.9	43
141	A role for ezrin in a neglected metastatic tumor function. Trends in Molecular Medicine, 2004, 10, 249-250.	6.7	31
142	Adoptive transfer of an anti-MART-12735-specific CD8+ Tâ€„cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. European Journal of Immunology, 2003, 33, 556-566.	2.9	48
143	Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin. Laboratory Investigation, 2003, 83, 1555-1567.	3.7	89
144	Leukocyte uropod formation and membrane/cytoskeleton linkage in immune interactions. Journal of Leukocyte Biology, 2003, 73, 556-563.	3.3	66

#	Article	IF	Citations
145	Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles. Journal of Experimental Medicine, 2002, 195, 1303-1316.	8.5	660
146	P-glycoproteinâ€"actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood, 2002, 99, 641-648.	1.4	134
147	Epithelial cells and expression of the phagocytic marker CD68: scavenging of apoptotic bodies following Rho activation. Toxicology in Vitro, 2002, 16, 405-411.	2.4	31
148	Importance of the state of activation and/or differentiation of CD4+ T cells in AIDS pathogenesis. Trends in Immunology, 2002, 23, 128-129.	6.8	6
149	Differential expression and distribution of ezrin, radixin and moesin in human natural killer cells. European Journal of Immunology, 2002, 32, 3059-3065.	2.9	28
150	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunological Reviews, 2002, 188, 97-113.	6.0	246
151	Rho-activating Escherichia coli cytotoxic necrotizing factor 1: macropinocytosis of apoptotic bodies in human epithelial cells. International Journal of Medical Microbiology, 2001, 291, 551-554.	3.6	20
152	GD3 glycosphingolipid contributes to Fas-mediated apoptosis via association with ezrin cytoskeletal protein. FEBS Letters, 2001, 506, 45-50.	2.8	49
153	Corrigendum to: GD3 glycosphingolipid contributes to Fas mediated apoptosis via association with ezrin cytoskeletal protein (FEBS 25182). FEBS Letters, 2001, 508, 494-494.	2.8	1
154	Expression of CCR-7, MIP-3Î², and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood, 2001, 98, 3022-3029.	1.4	231
155	Activation of Rho GTPases by Cytotoxic Necrotizing Factor 1 Induces Macropinocytosis and Scavenging Activity in Epithelial Cells. Molecular Biology of the Cell, 2001, 12, 2061-2073.	2.1	78
156	Murine granulocytes control human tumor growth in SCID mice. International Journal of Cancer, 2000, 87, 569-573.	5.1	24
157	Primary HIV-1 infection of human CD4+ T cells passaged into SCID mice leads to selection of chronically infected cells through a massive Fas-mediated autocrine suicide of uninfected cells. Cell Death and Differentiation, 2000, 7, 37-47.	11.2	12
158	CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO Journal, 2000, 19, 5123-5134.	7.8	203
159	Linkage between cell membrane proteins and actin-based cytoskeleton: the cytoskeletal-driven cellular functions. Histology and Histopathology, 2000, 15, 539-49.	0.7	25
160	Murine interferon-Î±1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-Î±/Î² therapy. Cancer Gene Therapy, 1999, 6, 246-253.	4.6	9
161	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4+ T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. Virology, 1999, 263, 78-88.	2.4	57
162	Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. European Journal of Immunology, 1999, 29, 1202-1208.	2.9	120

#	ARTICLE	IF	CITATIONS
163	Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. Journal of Virology, 1999, 73, 6453-6459.	3.4	43
164	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. Transplantation, 1998, 65, 416-420.	1.0	17
165	Human Lymphoblastoid CD4 ⁺ T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 ⁺ T-Cell Differentiation in Pathogenesis of AIDS. Journal of Virology, 1998, 72, 10323-10327.	3.4	12
166	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Research, 1997, 36, 81-90.	4.1	19
167	The biological relevance of polykaryons in the immune response. Trends in Immunology, 1997, 18, 522-527.	7.5	27
168	T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. Journal of Virology, 1996, 70, 7958-7964.	3.4	49
169	Unidirectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of intercellular adhesion molecules and HIV-1 viral matrix protein. Aids, 1995, 9, 329-335.	2.2	51
170	Antibody to ICAM-1 mediates enhancement of HIV-1 infection of human endothelial cells. Archives of Virology, 1995, 140, 951-958.	2.1	12
171	Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin. Archives of Virology, 1995, 140, 1849-1854.	2.1	14
172	Regulation of U-937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents. Nephrology Dialysis Transplantation, 1995, 10, 481-489.	0.7	24
173	HIV Type 1 Grown on Interferon Î³-Treated U937 Cells Shows Selective Increase in Virion-Associated Intercellular Adhesion Molecule 1 and HLA-DR and Enhanced Infectivity for CD4-Negative Cells. AIDS Research and Human Retroviruses, 1995, 11, 547-553.	1.1	55
174	Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines.. Gut, 1995, 37, 798-801.	12.1	26
175	Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology, 1995, 109, 1029-1038.	1.3	120
176	Recently recruited monocyte/macrophages and naive T-cells contribute to submucosal perivascular infiltrates in Crohn's disease (CD). Gastroenterology, 1995, 108, A789.	1.3	0
177	Persistent In Vivo Activation and Transient Anergy to TCR/CD3 Stimulation of Normal Human Intestinal Lymphocytes. Advances in Experimental Medicine and Biology, 1995, 371A, 43-46.	1.6	1
178	Unidirectional budding of HIV-1 at the site of cell-to-cell contact is associated with co-polarization of intercellular adhesion molecules and HIV-1 viral matrix protein. Aids, 1995, 9, 329-335.	2.2	56
179	THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT. Transplantation, 1995, 60, 1306-1313.	1.0	18
180	THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT. Transplantation, 1995, 60, 1306-1313.	1.0	1

#	Article	IF	Citations
181	A Simple and Reliable Method to Detect Cell Membrane Proteins on Infectious Human Immunodeficiency Virus Type 1 Particles. Journal of Infectious Diseases, 1994, 169, 886-889.	4.0	72
182	Interferon Expression in Crohn's Disease Patients: Increased Interferon-Î³ and -Î± mRNA in the Intestinal Lamina Propria Mononuclear Cells. Journal of Interferon Research, 1994, 14, 235-238.	1.2	61
183	Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity. Peptides, 1994, 15, 1033-1036.	2.4	17
184	Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin a production by intestinal lamina propria lymphocytes. Gastroenterology, 1994, 106, 576-582.	1.3	39
185	Continuousin vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. European Journal of Immunology, 1993, 23, 3104-3108.	2.9	77
186	Coordinate Induction of Interferon Î± and Î³ by Recombinant HIV-1 Glycoprotein 120. AIDS Research and Human Retroviruses, 1993, 9, 957-962.	1.1	43
187	Gliadin induced changes in the expression of MHC-class II antigens by human small intestinal epithelium. Organ culture studies with coeliac disease mucosa.. Gut, 1992, 33, 472-475.	12.1	56
188	Interferon-alpha (IFN-alpha) production by human intestinal mononuclear cells. Response to virus in control subjects and in Crohn's disease.. Gut, 1992, 33, 897-901.	12.1	12
189	MHC class II antigens on the epithelial cells of the human gastrointestinal tract. Gastroenterology, 1992, 102, 377-378.	1.3	3
190	Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Regulatory Peptides, 1992, 38, 79-87.	1.9	39
191	Gut neuropeptides and the immune system. Advances in Neuroimmunology, 1991, 1, 173-179.	1.8	4
192	Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. Journal of Neuroimmunology, 1991, 31, 211-219.	2.3	50
193	Usefulness of fecal ?1-antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in crohn's disease. Digestive Diseases and Sciences, 1991, 36, 347-352.	2.3	40
194	Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers.. Gut, 1991, 32, 403-407.	12.1	153
195	Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans. Gastroenterology, 1990, 98, 1693-1698.	1.3	13
196	A limiting-dilution analysis of activated circulating B cells in Crohn's disease. Journal of Clinical Immunology, 1990, 10, 128-134.	3.8	8
197	Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Gastroenterology, 1989, 97, 1435-1441.	1.3	31
198	The Clinical Significance of Serum C Reactive Protein Levels in CrohnÊ¼s Disease. Journal of Clinical Gastroenterology, 1988, 10, 401-405.	2.2	165

#	Article	IF	Citations
199	Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.. Gut, 1987, 28, 745-753.	12.1	172
200	Peripheral and intestinal lymphocyte activation after in vitro exposure to cow's milk antigens in normal subjects and in patients with Crohn's disease. Clinical Immunology and Immunopathology, 1987, 45, 491-498.	2.0	8
201	Isotypic Analysis of Antibody Response to a Food Antigen in Inflammatory Bowel Disease. International Archives of Allergy and Immunology, 1985, 78, 81-85.	2.1	18